Feature Channels: Clinical Trials

Filters close
Released: 24-May-2022 12:40 PM EDT
Medicare Program Spent $1.8 Billion in 2019 on Drugs Without Confirmed Clinical Benefits
Johns Hopkins Bloomberg School of Public Health

Study found that some drugs were on the market for over five years with no confirmed clinical benefit.

Newswise: Expert available to comment on improving representation in clinical trials and research
Released: 24-May-2022 12:00 PM EDT
Expert available to comment on improving representation in clinical trials and research
Indiana University

Indiana University's Amy Knopf can speak about the impacts of a recent National Academies of Sciences, Engineering, and Medicine report, "Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups."

Released: 24-May-2022 11:00 AM EDT
Susan G. Komen Awards Grant to Define and Advance Diagnosis of Inflammatory Breast Cancer
Susan G. Komen

Susan G. Komen awarded a research grant to apply a new, first-of-its-kind tool that seeks to more accurately diagnose inflammatory breast cancer (IBC).

Released: 23-May-2022 9:00 AM EDT
V-Wave's Ventura® Interatrial Shunt: One Year Follow-up from RELIEVE-HF Roll-in Arm Shows Improved Left and Right Ventricular Function in Patients with Advanced Heart Failure
V-Wave Ltd.

V-Wave Ltd, manufacturer of the V-Wave Ventura investigational interatrial shunt device to help patients with advanced heart failure (HF), announced 12-month echocardiographic results from the open label Roll-in arm of the RELIEVE-HF pivotal clinical trial, comprising 97 NYHA Class III or ambulatory Class IV HF patients who were already on maximally tolerated guideline directed medical therapy.

Released: 19-May-2022 2:50 PM EDT
Study tests link between common blood pressure pills and breast cancer
Curtin University

Curtin University researchers will examine if the long-term use of a popular blood pressure medication increased the risk of breast cancer in almost 200,000 women as part of a new project supported by the Federal Government.

Newswise: Imatinib Shows Improved Outcomes for Patients with Severe COVID-19 in the CounterCOVID Clinical Trial
9-May-2022 4:00 PM EDT
Imatinib Shows Improved Outcomes for Patients with Severe COVID-19 in the CounterCOVID Clinical Trial
American Thoracic Society (ATS)

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.

Newswise: New Weight-Loss Intervention Targets Instinctive Desire to Eat
17-May-2022 1:35 PM EDT
New Weight-Loss Intervention Targets Instinctive Desire to Eat
University of California San Diego

People who are highly responsive to food lost more weight and kept it off using a new weight loss program that targets internal hunger cues and the ability to resist food, reports University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science.

Newswise: After Sprint for COVID-19 Vaccines, HVTN Researchers Return to HIV Marathon With Fresh Determination and Knowledge, Launch Clinical Research Registry and Ad Campaign
Released: 18-May-2022 9:55 AM EDT
After Sprint for COVID-19 Vaccines, HVTN Researchers Return to HIV Marathon With Fresh Determination and Knowledge, Launch Clinical Research Registry and Ad Campaign
HIV Vaccine Trials Network

SEATTLE (May 18, 2022) – Building on momentum from the highly successful COVID-19 vaccine clinical trials, the HIV Vaccine Trials Network (HVTN) is launching a new HIV awareness campaign and unveiling a first-of-its-kind national registry that will provide updated HIV information and make it easier to learn about and participate in HIV clinical trials at HelpEndHIV.org.

Released: 17-May-2022 9:05 AM EDT
Pulmonary Fibrosis Foundation Expands Clinical Trial Resources for Patients
Pulmonary Fibrosis Foundation

The Pulmonary Fibrosis Foundation (PFF) has developed new materials and tools for people living with pulmonary fibrosis (PF) to learn about and enroll in clinical research studies.

Released: 15-May-2022 2:05 PM EDT
Researchers Find Favorable Tradeoffs of PSA Screening for Prostate Cancer
University Hospitals Cleveland Medical Center

University Hospitals’ Jonathan Shoag, MD, and a team of researchers from Case Western Reserve University and the Case Comprehensive Cancer Center, Weill Cornell Medical Center, the Fred Hutchinson Cancer Research Center, and others, set out to assess the tradeoffs of PSA screening using long-term epidemiologic data. “No matter the assumptions,” Shoag said, “the data showed lower numbers than prior estimates, many in the low single digits, for the number needed to treat to prevent a prostate-cancer death. This result was observed in all men, and especially for Black men.” The researchers presented their findings in a late-breaking abstract at the American Urological Association’s annual meeting this month and the study was published May 15 in The New England Journal of Medicine Evidence.

Newswise: Early Study Finds New Lymphoma Drug Effective
Released: 13-May-2022 10:50 AM EDT
Early Study Finds New Lymphoma Drug Effective
Michigan Medicine - University of Michigan

In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma.

Released: 13-May-2022 2:00 AM EDT
Multimodal Chronic Pain Therapy for Adults via Smartphone: Randomized Controlled Clinical Trial
Journal of Medical Internet Research

Background: Combination therapies delivered remotely via the internet or mobile devices are increasingly being used to improve and promote the self-management of chronic conditions. However, little is known regarding the long-term ef...

Newswise: Fast-tracked: First in-human trial for aggressive brain tumours
Released: 12-May-2022 12:05 AM EDT
Fast-tracked: First in-human trial for aggressive brain tumours
University of South Australia

A novel technology designed to precisely image aggressive brain cancers and guide treatment is being developed by the University of South Australia and Australian cancer diagnostic company, Ferronova, potentially helping thousands of people who are diagnosed with the deadly condition each year.

Released: 11-May-2022 8:00 AM EDT
First Patients Dosed in Phase 2 Platform Clinical Trial Testing Novel Immunotherapy Combinations in Highly Malignant Ovarian Cancer
Cancer Research Institute (CRI) and Ovarian Cancer Research Alliance (OCRA)

A phase 2 clinical trial testing novel immunotherapy combinations in aggressive ovarian cancer has opened and first patients have begun treatment.

Released: 9-May-2022 3:10 PM EDT
Quantifying Cognitive Decline in Dogs Could Help Humans With Alzheimer’s Disease
North Carolina State University

A suite of complimentary tests can quantify changes in dogs suspected of suffering from cognitive decline. The approach could benefit dogs and serve as a model for evaluating cognitive decline progression in – and treatments for – humans with Alzheimer’s disease.

8-May-2022 11:00 AM EDT
Targeting Interleukin-6 Could Help Relieve Immunotherapy Side Effects
University of Texas M. D. Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6).

Newswise: SarahMurthi.JPG
Released: 6-May-2022 3:00 PM EDT
University of Maryland School of Medicine Helps Launch New Center to Accelerate Advancement of Virtual Reality into Patient Care
University of Maryland School of Medicine

The University of Maryland School of Medicine (UMSOM) is the joint recipient of $4.75 million in funding from the National Science Foundation to establish a new Center for Medical Innovations in Extended Reality.

Released: 4-May-2022 2:45 PM EDT
Regulatory Frameworks for Clinical Trial Data Sharing: Scoping Review
Journal of Medical Internet Research

Background: Although well recognized for its scientific value, data sharing from clinical trials remains limited. Steps toward harmonization and standardization are increasing in various pockets of the global scientific community. Th...

Newswise: Investigating Cancer Drug Toxicity Leads to a Critical Discovery
29-Apr-2022 3:00 PM EDT
Investigating Cancer Drug Toxicity Leads to a Critical Discovery
La Jolla Institute for Immunology

When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.

Newswise: Stroke Patient with Brain Injury Fully Recovers After Participating in UTHealth Houston-Led Clinical Trial
Released: 3-May-2022 8:05 AM EDT
Stroke Patient with Brain Injury Fully Recovers After Participating in UTHealth Houston-Led Clinical Trial
University of Texas Health Science Center at Houston

A stroke and subsequent brain injury qualified 65-year-old Linda Carmichael for a national, randomized clinical trial led locally by Sunil A. Sheth, MD, with McGovern Medical School at UTHealth Houston, investigating the safety and efficacy of endovascular thrombectomy plus medical management compared to medical management alone in certain LVO stroke patients.

Newswise: Magnetic Therapy Pioneered by NUS Researchers Enhances Chemotherapy Treatment of Breast Cancer
Released: 2-May-2022 10:05 PM EDT
Magnetic Therapy Pioneered by NUS Researchers Enhances Chemotherapy Treatment of Breast Cancer
National University of Singapore

A team of researchers from the National University of Singapore is pioneering a novel magnetic therapy as an effective companion therapy to chemotherapy for treatment of breast cancer. This therapy is localised, non-invasive and painless, and could improve the overall treatment outcome.

Released: 2-May-2022 3:50 PM EDT
Ochsner Performs First Procedure in Baton Rouge with New Pacemaker Technology
Ochsner Health System

Ochsner Baton Rouge electrophysiologist Dr. Freddy Abi-Samra has successfully completed the region’s first heart pacemaker procedure in a clinical trial involving a new, breakthrough technology that could make pacemaker surgery available to patients who may not benefit from traditional technology.

Released: 2-May-2022 10:35 AM EDT
TOGETHER trial named David Sackett Trial of the Year 2021
Society for Clinical Trials

The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to The TOGETHER Trial: An Adaptive Platform International Trial.

Released: 29-Apr-2022 11:05 AM EDT
Insulin Spray Improved Gait, Cognitive Function in Patients with and Without Type 2 Diabetes, Clinical Trial Shows
Beth Israel Deaconess Medical Center

Scientists have assessed the long-term effects of intranasal insulin on cognition and on gait in people with and without type 2 diabetes mellitus.

22-Apr-2022 4:05 PM EDT
Does the drug dapagliflozin benefit hospitalized patients with COVID-19?
American Society of Nephrology (ASN)

In hospitalized patients with COVID-19, the SGLT2 inhibitor dapagliflozin was well tolerated regardless of kidney function, but did not significantly lower patients’ risk of organ failure, kidney problems, or death compared with placebo.

Newswise: Changing Guidelines for Treating Mild Chronic Hypertension in Pregnancy
Released: 28-Apr-2022 10:05 AM EDT
Changing Guidelines for Treating Mild Chronic Hypertension in Pregnancy
Ochsner Health System

Based upon a clinical trial of pregnant women at more than 70 sites, including Ochsner Health, doctors are recommending that even mild forms of high blood pressure be treated with medication.

Newswise: Montefiore Einstein Cancer Center Finds CAR-T Therapy Effective in Black and Hispanic Patients
27-Apr-2022 3:40 PM EDT
Montefiore Einstein Cancer Center Finds CAR-T Therapy Effective in Black and Hispanic Patients
Albert Einstein College of Medicine

CAR-T therapy, a form of immunotherapy that revs up T-cells to recognize and destroy cancer cells, has revolutionized the treatment of blood cancers, including certain leukemias, lymphomas, and most recently, multiple myeloma. However, Black and Hispanic people were largely absent from the major clinical trials that led to the U.S. Food and Drug Administration approval of CAR-T cell therapies.

Newswise: Cardiologists, Cardiothoracic Surgeons Available for Expert Commentary Ahead of Upcoming Conferences
Released: 27-Apr-2022 11:05 AM EDT
Cardiologists, Cardiothoracic Surgeons Available for Expert Commentary Ahead of Upcoming Conferences
Cedars-Sinai

Cardiologists and cardiothoracic surgeons from the Smidt Heart Institute at Cedars-Sinai are available to discuss the latest advances in research, clinical care, transcatheter procedures and cardiothoracic surgery throughout the International Society for Heart and Lung Transplantation (ISHLT) Scientific Sessions 2022 and Heart Rhythm 2022.

Released: 27-Apr-2022 11:05 AM EDT
Wake Forest University School of Medicine Researchers Receive $1.7 Million Grant to Study Obesity Medication
Wake Forest School of Medicine

With the support of a $1.7 million grant from the National Institutes of Health, researchers at the School of Medicine will lead the Long-term Effectiveness of the Anti-Obesity medication Phentermine (LEAP) trial, a placebo-controlled, randomized-controlled trial that will enroll 1,000 adults at five sites across the U.S.

Newswise: Immunotherapy Study Offers Hope for Pancreatic Cancer Patients
Released: 27-Apr-2022 11:05 AM EDT
Immunotherapy Study Offers Hope for Pancreatic Cancer Patients
Sylvester Comprehensive Cancer Center

In a research letter to the journal JAMA Oncology, clinical researchers at Sylvester Comprehensive Cancer Center in the University of Miami Miller School of Medicine showed that immunotherapy can be an option for at least one subgroup of pancreatic cancer patients. The study found that patients with inherited BRCA and other similar mutations can achieve complete responses — in some cases going from near death to durable recoveries.

Released: 26-Apr-2022 2:05 PM EDT
Blasting Bladder Cancer
University of New Mexico Comprehensive Cancer Center

Bladder cancer affects nearly 84,000 people in the United States each year, making it the sixth most common cancer. Most people survive it, but unfortunately, many lose their bladders. Neda Hashemi, MD, and her team at The University of New Mexico Comprehensive Cancer Center are now offering several clinical trials, including one that will give people with bladder cancer a chance to fight their disease and keep their bladders.

Newswise: Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer
Released: 25-Apr-2022 9:45 AM EDT
Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer
Yale Cancer Center

The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center and participating organizations.

Released: 19-Apr-2022 12:55 PM EDT
Sylvester Pancreatic Cancer Research Institute Takes on the Toughest Tumors
Sylvester Comprehensive Cancer Center

Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently established the Sylvester Pancreatic Cancer Research Institute (SPCRI). The new center will support innovative research, increase collaborations between scientists and clinicians, and provide more treatment and clinical trial opportunities for patients.

Released: 15-Apr-2022 10:25 AM EDT
Rilzabrutinib for blood disorder shows promise in phase 1–2 clinical trial
Massachusetts Institute of Technology (MIT)

Drug may safely boost platelet levels in patients with immune thrombocytopenia.

Released: 12-Apr-2022 9:00 AM EDT
Researchers outline need for new approach to COVID-19 vaccine testing
Institute for Health, Health Care Policy and Aging Research at Rutgers University

Rutgers researchers are calling for a change in our approach to developing COVID-19 vaccines, and vaccines to fight future pandemics, to incorporate both conventional and challenge trails.

Released: 11-Apr-2022 2:05 PM EDT
Department of Energy Announces $1 Million for Research on Studies to Accelerate the Evaluation of Novel, Medical Isotopes for Use in Preclinical and Clinical Medical Trials
Department of Energy, Office of Science

Today, the U.S. Department of Energy (DOE) announced $1 million in funding for three awards to advance research and development (R&D) to translate newly developed radioisotopes into evaluation for potential use in preclinical and clinical trials. This funding is part of a key federal program that produces critical isotopes otherwise unavailable or in short supply for U.S. science, medicine, and industry.

Newswise: Advancing a Treatment for a Common Eye Disease That Lacks One
Released: 11-Apr-2022 11:05 AM EDT
Advancing a Treatment for a Common Eye Disease That Lacks One
NIH, National Eye Institute (NEI)

The road from discovering a potential drug to getting the therapy into the hands of patients is a long and uncertain one. An NIH program offers researchers a smoother path from basic science to clinical testing and regulatory approval.

Newswise: Hackensack Meridian Hackensack University Medical Center Studying the Effect of Omega-3 Supplements on Post-COVID Recovery
Released: 11-Apr-2022 7:05 AM EDT
Hackensack Meridian Hackensack University Medical Center Studying the Effect of Omega-3 Supplements on Post-COVID Recovery
Hackensack Meridian Health

Hackensack Meridian Hackensack University Medical Center started a new study investigating the impact of omega-3 supplements on post-COVID symptoms.

Released: 10-Apr-2022 5:20 PM EDT
Therapies targeting DNA damage response show promising antitumor activity
University of Texas M. D. Anderson Cancer Center

New data from MD Anderson-led studies on ATR inhibitor and next-generation PARP1 inhibitor presented at AACR Annual Meeting

Newswise: Roswell Park’s Dr. Grace Dy Presents Long-Term Data on CodeBreaK 100 Sotorasib Study
9-Apr-2022 2:05 PM EDT
Roswell Park’s Dr. Grace Dy Presents Long-Term Data on CodeBreaK 100 Sotorasib Study
Roswell Park Comprehensive Cancer Center

New data to be presented by Grace Dy, MD, at the American Association for Cancer Research Annual Meeting show that patients with non-small cell lung cancer (NSCLC) who received the targeted therapy sotorasib experienced extended survival and good quality of life.

Newswise: Stress Receptors Explored as Possible Immune Checkpoint, Suggesting Role for Beta-Blockers in Cancer Treatment
Released: 9-Apr-2022 10:05 AM EDT
Stress Receptors Explored as Possible Immune Checkpoint, Suggesting Role for Beta-Blockers in Cancer Treatment
Roswell Park Comprehensive Cancer Center

Combining a beta-blocker with the cancer immunotherapy drug pembrolizumab could be a promising new treatment option for many hard-to-treat solid-tumor cancers. Researchers from Roswell Park Comprehensive Cancer Center will report on a study of of this treatment combination in patients with advanced or metastatic melanoma at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Newswise: Pawel%20Kalinski%20and%20Shipra%20Gandhi%20DOD%20Grant%20September%2012%2C%202019%208.jpeg
Released: 9-Apr-2022 10:05 AM EDT
Researchers Seek to Expand Immunotherapy Options for Patients with Advanced Breast and Colorectal Cancer
Roswell Park Comprehensive Cancer Center

Two Roswell Park Comprehensive Cancer Center oncologists will discuss promising strategies for making breakthrough immunotherapies work for more patients at the annual meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana, on Monday, April 11.

Released: 8-Apr-2022 12:35 PM EDT
Clinical trials often fail to cite relevant past studies, researchers find
Cell Press

Clinical trials are a pivotal tool for assessing the safety and efficacy of medical interventions, but sponsors often provide incomplete information for assessing their ethical justification.

Newswise: UC San Diego Joins National Trial to Explore New Vaccines for COVID-19 Variants
Released: 6-Apr-2022 1:15 PM EDT
UC San Diego Joins National Trial to Explore New Vaccines for COVID-19 Variants
University of California San Diego Health

UC San Diego has joined a Phase II clinical trial to evaluate various additional COVID-19 booster shots. The trial seeks to understand if different vaccine regimens can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.

Newswise: New Immunotherapy Platform, Role of Stress in Cancer Highlight Roswell Park’s AACR 2022 Presentations
Released: 6-Apr-2022 10:00 AM EDT
New Immunotherapy Platform, Role of Stress in Cancer Highlight Roswell Park’s AACR 2022 Presentations
Roswell Park Comprehensive Cancer Center

Dozens of cancer specialists at Roswell Park Comprehensive Cancer Center have been invited to present their latest advances in cancer research at the annual meeting of the American Association for Cancer Research (AACR), which will take place in New Orleans, Louisiana, from April 8 to 13.

Released: 5-Apr-2022 3:55 PM EDT
The latest news on clinical trials is here on Newswise
Newswise

Here are some of the latest articles that have been added to the Clinical Trials channel on Newswise.

Released: 5-Apr-2022 8:05 AM EDT
CEFALY Publishes the First and Largest, Phase 3 Clinical Trial of 2-hour External Trigeminal Nerve Stimulation (e-TNS) for At-Home Acute Migraine Treatment
Cefaly Technology

CEFALY Technology, a Belgium-based manufacturer of wearable medical devices for migraine, today announced the results of a clinical study demonstrating that two-hour treatment with the e-TNS CEFALY device is a safe and effective, non-pharmaceutical alternative for the acute treatment of migraine attacks in the out-of-hospital setting.

Released: 5-Apr-2022 8:00 AM EDT
UCSF, QLHC and FDA Announce Successful Deployment of Innovative Data Capture System for Clinical Care and Research
University of California, San Francisco (UCSF)

UCSF, in collaboration QLHC and the FDA, has developed the OneSource electronic data capture (EDC) system to seamlessly integrate clinical care and research by streamlining collection and distribution of patient health data for clinical trials. It is currently being deployed in the I-SPY COVID trial and expanding to I-SPY 2.2 trial for breast cancer.

Newswise: Minority Representation in Clinical Trials is Critical
Released: 4-Apr-2022 9:00 AM EDT
Minority Representation in Clinical Trials is Critical
Rutgers Cancer Institute of New Jersey

Addressing disparities in cancer care, including access to and participation in clinical trials, has long been a priority for Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health. Sanjay Goel, MD, MS, director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute shares more.


Showing results

150 of 1300

close
0.85071